How precision medicine is reshaping brain cancer treatment
Brain cancer is not a single disease. Gliomas, meningiomas, lymphomas and metastatic tumours can all look different on an MRI, yet their treatment may depend on molecular features that cannot be seen on imaging. Precision medicine brings those features into treatment decisions, pairing a tumour’s genetic, epigenetic and protein profile with a drug, a clinical trial or a carefully monitored course of standard care.
The shift matters because treatment selection has become more individual. A pathology report can reveal a rare subtype and a target; a DNA assay can clarify prognosis when appearance and grade are uncertain; a biomarker can expose a treatment whose benefit would otherwise be missed. For neurosurgeons, oncologists, pathologists and patients, the task is to integrate this information with anatomy, age, other illnesses and personal goals. Independent clinical perspectives can help place those decisions within a wider culture of reflective practice.
| Clinical approach | Information used | Decision supported | Important limitation |
|---|---|---|---|
| Standard care | Clinical assessment, imaging and conventional pathology | Surgery, radiotherapy and standard medicines | Molecular detail may still be missing |
| Molecularly guided therapy | Sequencing, methylation or protein testing | A targeted drug matched to an actionable alteration | A match does not guarantee benefit, approval or funding |
| Research-led matching | Molecular profile plus eligibility criteria | Access to investigational or matched treatments | Availability, travel and the maturity of evidence vary |
Reading the molecular biology of a brain tumour
Much of the change starts in pathology. Where tissue is available, neuro-oncology teams may use next-generation sequencing, a focused DNA or RNA panel, or methylation analysis to classify difficult tumours and identify potentially actionable changes. The specimen, assay and question matter: a surgical sample may answer more than a blood test, while a broad panel can detect unexpected targets at greater cost. Australian pathology services have increasingly integrated molecular testing into major neuro-oncology centres in Sydney, Melbourne, Brisbane and Perth.
The results must be interpreted in their biological context. An IDH mutation can influence prognosis and management in diffuse glioma; MGMT promoter methylation predicts greater temozolomide benefit in glioblastoma; a BRAF V600E alteration may support targeted treatment in melanoma; and NTRK fusions or ERBB2 changes can open options in particular metastatic tumours. No marker travels alone. A target in the laboratory becomes useful only when its location, tumour type, treatment history and available evidence align.
Liquid biopsy offers another route when tissue is scarce or repeated sampling is impractical. Circulating tumour DNA can help monitor selected disease or study resistance, although low shedding from some brain tumours limits sensitivity. It usually complements rather than replaces tissue diagnosis. This distinction prevents an attractive test from becoming a shortcut, especially when surgery could provide both diagnosis and debulking.
Matching therapy to the right alteration
Standard care has not been displaced. Suitable patients with glioblastoma still commonly receive maximal safe resection followed by radiotherapy and temozolomide, while molecular findings refine prognosis, trial options and toxicity management. In selected low-grade glioma, evidence now supports treatment choices based on IDH status, including use of the IDH inhibitor vorasidenib in appropriate adults. Its availability in Australia does not remove the need for specialist review of surgery, radiation and long-term monitoring.
Targeted treatment is most convincing when the alteration and disease setting match the evidence. BRAF inhibition may benefit selected melanoma brain metastases; HER2-directed medicines can be valuable in metastatic breast cancer; and NTRK inhibitors have activity in some fusion-positive solid tumours. These examples show why a genomic report needs interpretation rather than automatic prescribing. Interactions with anticonvulsants, anticoagulants and other medicines can alter exposure or safety.
Immunotherapy adds another layer. Molecular subsets, previous treatment and the tumour microenvironment can influence response, yet many immune-based approaches have not shown routine benefit in unselected glioblastoma. Trial eligibility increasingly depends on a molecular profile. The result is a more conditional treatment conversation: a target may indicate an option, while the strength, timing and funding of that option depend on the disease itself.
Australia’s regulatory and access pathways
Australian practice operates through a mixed public and private market. Public patients usually reach neuro-oncology services through a hospital referral and Medicare, often involving multidisciplinary clinics. Private treatment can shorten access to some specialists, but out-of-pocket costs vary sharply. Specialist capacity is concentrated in major cities, so a patient in regional or rural Australia may need travel, telehealth or coordinated care closer to home. These pathways shape which molecular tests and medicines are realistic, not simply whether evidence exists.
Regulation and reimbursement are separate checkpoints. The Therapeutic Goods Administration assesses medicines for safety, quality and efficacy before Australian marketing. The Australian New and Joint Government Committee on Therapeutic Products then advises on public subsidy through the Pharmaceutical Benefits Scheme, where relevant. A TGA approval does not automatically mean PBS funding, and PBS restrictions can determine which patients, indications or prescribers qualify. Molecular testing has its own coverage variations, so an ordering clinician should check local pathways before testing.
Market access therefore belongs in the treatment plan from the start. Targeted medicines may be available through specialist prescribing, public hospital formularies or trial funding. Australian brain cancer research has also been strengthened by Medical Research Future Fund investment, helping connect laboratory discoveries with trials and clinical delivery. These systems can support innovation, although the benefit still depends on affordability, timely diagnosis and access to a team able to interpret the evidence.
Safety, surgery and daily treatment
Targeted therapy does not remove familiar safety work. In Australia, strong sun exposure makes skin monitoring especially important for medicines associated with photosensitivity, including some EGFR inhibitors. Pharmacy reviews should check other regular medicines, and patients need clear advice about fatigue, driving and warning signs. A stable routine matters: scripts, blood tests and appointments can be difficult to manage alongside work, travel or caring responsibilities, particularly when treatment cycles do not align neatly with monthly budgets.
Neurosurgical judgement remains central even when a molecular result points towards systemic therapy. Decisions about biopsy, extent of resection and the timing of postoperative treatment still depend on anatomy and clinical condition. A detailed account of subarachnoid haemorrhage care offers a useful reminder of neurocritical care: a procedure can succeed while complications still require close observation and prompt action.
Daily function deserves equal attention. Seizure control, cognitive effects, mood, speech and mobility can shape recovery more than a small change in tumour volume. Occupational therapy, neuropsychology, speech pathology and a driving assessment may be as important as another scan. In Brisbane or Adelaide, a patient may combine hospital appointments with rehabilitation, family support and return-to-work goals. The plan must treat the person as well as the tumour markers.
Research, data and the next clinical frontier
The next step is evidence that matches the pace of discovery. Trials stratified by molecular findings can test whether a biomarker predicts response, yet recruitment rules become restrictive when rare subgroups are spread across Australia. Remote participation, shared protocols and national tumour banking can widen access, provided investigators address travel, consent and follow-up. Ongoing clinical news updates are a practical way to track new studies and regulatory developments, but primary trial reports and official guidance should guide clinical decisions.
Genomic information also creates responsibilities. For covered organisations, Australia’s Privacy Act 1988 and Australian Privacy Principles set important requirements for sensitive health data, including genomic information. Consent must address secondary use, storage and possible family implications if a germline finding is detected. Clinicians need a clear pathway for genetic counselling and for explaining uncertain or incidental findings without alarming patients or implying that a laboratory signal guarantees future disease.
Equity cannot be assumed from technical progress. Aboriginal and Torres Strait Islander communities should guide decisions about genomic research, data governance and the use of stored samples. Services should also avoid assuming that a treatment pathway suitable for a metropolitan patient will work for someone travelling long distances between imaging, pathology and day treatment. Precision medicine will be judged by outcomes and access, not by the sophistication of its vocabulary.
Brain cancer treatment is becoming more molecular, but it remains deeply clinical. The strongest decisions connect a validated result with a suitable treatment, a realistic access pathway and a patient’s priorities. Surgeons, oncologists, pathologists, allied health professionals and primary care clinicians all have a role in checking that the chain holds. Thamburaj offers a neurosurgical perspective on that process through case reflections, clinical commentary and educational material for clinicians and students.
Create an account on Thamburaj to post, reply and subscribe to updates. Join the open peer discussion forum to exchange evidence-based observations, browse the curated neurosurgery and medicine e-library, and share a case-based insight as new developments in brain cancer care emerge.